omtriptolide: a water-soluble, semisynthetic derivative of PG490 (triptolide) purified from the Chinese herb Tripterygium Wilfordii; structure in first source [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 6918522 |
| CHEMBL ID | 2110669 |
| SCHEMBL ID | 16312527 |
| MeSH ID | M0578170 |
| Synonym |
|---|
| unii-d36elm729p |
| d36elm729p , |
| omtriptolide [inn] |
| pg490-88 |
| 195883-06-8 |
| omtriptolide |
| ym 262 |
| butanedioic acid, mono((3bs,4as,5ar,6r,6as,7as,7bs,8as,8bs)-1,3,3b,4,4a,6,6a,7a,7b,8b,9,10-dodecahydro-8b-methyl-6a-(1-methylethyl)-1-oxotrisoxireno(6,7:8a,9:4b,5)phenanthro(1,2-c)furan-6-yl) ester |
| 4-(((3bs,4as,5ar,6r,6as,7as,7bs,8as,8bs)-6a-isopropyl-8b-methyl-1-oxo-1,3,3b,4,4a,6,6a,7a,7b,8b,9,10-dodecahydrotrisoxireno(6,7:8a,9:4b,5)phenanthro(1,2-c)furan-6-yl)oxy)-4-oxobutanoic acid |
| omtriptolide [who-dd] |
| SCHEMBL16312527 |
| CHEMBL2110669 |
| CS-6982 |
| HY-16363 |
| Q27276034 |
| MS-28442 |
| 4-[[(1s,2s,4s,5s,7s,8r,9r,11s,13s)-1-methyl-17-oxo-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-8-yl]oxy]-4-oxobutanoic acid |
| VHA88306 |
| AKOS040742336 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.69%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (92.31%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| camptothecin | delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol | antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| irinotecan | carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound | antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| triptolide | diterpenoid; epoxide; gamma-lactam; organic heteroheptacyclic compound | antispermatogenic agent; plant metabolite | 2003 | 2020 | 12.0 | high | 0 | 0 | 0 | 1 | 3 | 0 | |
| tacrolimus | macrolide lactam | bacterial metabolite; immunosuppressive agent | 2005 | 2006 | 18.7 | high | 0 | 0 | 0 | 3 | 0 | 0 | |
| trelstar | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |||
| phenanthrenes | 2003 | 2020 | 12.0 | high | 0 | 0 | 0 | 1 | 3 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute Kidney Failure | 0 | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Acute Kidney Injury | 0 | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Acute Lung Injury | 0 | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Age-Related Osteoporosis | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Arthritis, Rheumatoid | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Benign Neoplasms | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Bronchiolitis Obliterans | 0 | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Bronchiolitis, Exudative | 0 | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Cancer of Colon | 0 | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Cancer of Lung | 0 | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Cardiovascular Diseases | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Colonic Neoplasms | 0 | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Disease Models, Animal | 0 | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Graft vs Host Disease | 0 | 2000 | 2002 | 23.0 | low | 0 | 0 | 1 | 1 | 0 | 0 | |
| Graft-Versus-Host Disease | 0 | 2000 | 2002 | 23.0 | low | 0 | 0 | 1 | 1 | 0 | 0 | |
| Injury, Ischemia-Reperfusion | 0 | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Lung Injury, Acute | 0 | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Lung Injury, Ventilator-Induced | 0 | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Lung Neoplasms | 0 | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Neoplasms | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Osteoporosis | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Reperfusion Injury | 0 | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Rheumatoid Arthritis | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Sensitivity and Specificity | 0 | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Article | Year |
|---|---|
| The Study of Cellular Mechanism of Triptolide in the Treatment of Cancer, Bone Loss and Cardiovascular Disease and Triptolide's Toxicity. Current stem cell research & therapy, , Volume: 15, Issue:1 | 2020 |
| Article | Year |
|---|---|
| Protective effects of PG490-88 on chronic allograft rejection by changing intragraft gene expression profiles. Transplantation proceedings, , Volume: 37, Issue:4 | 2005 |
| PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Molecular cancer therapeutics, , Volume: 2, Issue:9 | 2003 |